Resveratrol reduces the level of chronic systemic inflammation in stable coronary artery disease

Abstract

anti-adhesive, angiogenic, vasodilative and many other properties of polyphenols have been found out, which are implemented mainly through effects on molecular targets of intracellular cascades [4].One of the representatives of the plant polyphenol is phytoalexin resveratrol (3,4,5-trihydroxy-trans-stilbene) found in more than 30 kinds of plants and used in medicine as a natural extract and synthetic drug [5]. Resveratrol has a direct antiradical action by means of three hydroxyl groups in its chemical formula, regulates the activity of enzymes of cyclooxygenase (COX) and lipoxygenase (LOX), has antiinflammatory activity-it inhibits the pathogenic effect of a key factor of activating process of inflammation of NF-kB through inhibition of IkB-kinase α (IKKα), and has endothelio protective effect through activation of endothelial synthetase of nitric oxide (eNOS) as well [6][7][8].The aim of our research was to study the effects of resveratrol on the CSI indicators in stable CHD. Materials and methodsThe study involved 85 people of both sexes (36 females and 49 males) aged 48-67, diagnosed with CHD, stable angina pectoris, FC II, НF 0-І, the average risk. The selection of patients was carried out using an objective and instrumental examination: Rose angina questionnaires, SCORE table, bicycle ergometer and Doppler echocardiography. Every patient gave a written informed consent to participate in the research, according to the requirements of the Declaration of Helsinki. The criterion for inclusion into the study was signs of coronary